Crabb, Simon - University of Southampton

个人简介

Dr Crabb graduated in medicine from St George’s Hospital Medical School, London in 1996. He joined the University of Southampton in 2002 as a Cancer Research UK Clinical Research Fellow and was awarded his PhD in 2006 for work involving novel histone deacetylase inhibitors. Following a Clinical Research Fellowship at the BC Cancer Agency in Vancouver, he returned to the Cancer Sciences Unit in Southampton where he now works as an Associate Professor and Honorary Consultant in Medical Oncology.

研究领域

Dr Crabb’s research interests are in epigenetic therapeutic agents, mechanisms of systemic treatment resistance and the development of molecularly targeted therapeutic strategies. Primarily these interests are applied to bladder cancer and prostate cancer. In addition to laboratory work, he is an active clinical and translational researcher who leads and collaborates on a number of early phase clinical trials for genitourinary cancers.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC) - Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon J., Harshman, Lauren C., Bellmunt, Joaquim, De Giorgi, Ugo, Sternberg, Cora N., Cerbone, Linda, Ladoire, Sylvain, Wong, Yu-Ning, Yu, Evan Y., Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N., Pal, Sumanta K., Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W., Milowsky, Matthew I., Theodore, Christine, Berthold, Dominik R., Daugaard, Gedske, Sridhar, Srikala S., Powles, Thomas, Rosenberg, Jonathan E., Galsky, Matthew D. and Mariani, Luigi Published:2016Publication:European UrologyVolume:35, (1)Page Range:1-9doi:10.1016/j.eururo.2016.09.042PMID:27726966 IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial - Rini, Brian I., Stenzl, Arnulf, Zdrojowy, Romauld, Kogan, Mikhail, Shkolnik, Mikhail, Oudard, Stephane, Weikert, Steffen, Bracarda, Sergio, Crabb, Simon J., Bedke, Jens, Ludwig, Joerg, Maurer, Dominik, Mendrzyk, Regina, Wagner, Claudia, Mahr, Andrea, Fritsche, Jens, Weinschenk, Toni, Walter, Steffen, Kirner, Alexandra, Singh-Jasuja, Harpreet, Reinhardt, Carsten and Eisen, Tim Published:2016Publication:The Lancet OncologyPage Range:1-13doi:10.1016/S1470-2045(16)30408-9PMID:27720136 Epigenetic modulators as therapeutic targets in prostate cancer. - Graça, Inês, Pereira-Silva, Eva, Henrique, Rui, Packham, Graham, Crabb, Simon J. and Jerónimo, Carmen Published:2016Publication:Clinical EpigeneticsVolume:8, (98)Page Range:1-24doi:10.1186/s13148-016-0264-8PMID:27651838 Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11) - Cathomas, Richard, Crabb, Simon J., Mark, Michael, Winterhalder, Ralph, Rothermundt, Christian, Elliott, Tony, von Burg, Philippe, Kenner, Heike, Hayoz, Stefanie, Vilei, Simona Berardi, Rauch, Daniel, Roggero, Enrico, Mohaupt, Markus G., Bernhard, Jürg, Manetsch, Gabriela and Gillessen, Silke Published:2016Publication:The ProstatePage Range:1-9doi:10.1002/pros.23236PMID:27457964